Relovade    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病2

63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 311 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-001371-20-ES
(EUCTR)
15/10/201308/08/2013A study to provide continued access of eltrombopag to subjects who are currently participating in a GlaxoSmithKline sponsored investigational study with eltrombopag (parent study)Study 200170: A Rollover Study to Provide ContinuedTreatment with Eltrombopag - Eltrombopag rollover protocol Acute myelogenous leukemia & Idiopathic thrombocytopenic purpura (ITP
MedDRA version: 16.0;Level: LLT;Classification code 10000886;Term: Acute myeloid leukemia;System Organ Class: 100000004864
MedDRA version: 16.0;Level: PT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Relovade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Relovade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
GlaxoSmithKline, S.A.NULLNot RecruitingFemale: yes
Male: yes
100Phase 4United States;Hong Kong;Taiwan;Greece;Spain;Thailand;Ireland;Israel;Russian Federation;Italy;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Netherlands;Germany;Tunisia;China;Korea, Republic of
2EUCTR2013-001371-20-BE
(EUCTR)
15/10/201310/09/2013A study to provide continued access of eltrombopag to subjects who are currently participating in a GlaxoSmithKline sponsored investigational study with eltrombopag (parent study)Study 200170: A Rollover Study to Provide ContinuedTreatment with Eltrombopag - Eltrombopag rollover protocol Acute myelogenous leukemia & Idiopathic thrombocytopenic purpura (ITP
MedDRA version: 17.0;Level: LLT;Classification code 10000886;Term: Acute myeloid leukemia;System Organ Class: 100000004864
MedDRA version: 17.0;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: Revolade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Relovade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Relovade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Revolade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
Trade Name: Revolade
Product Name: Eltrombopag
Product Code: SB-497115
INN or Proposed INN: ELTROMBOPAG
GlaxoSmithKline Research and Development LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100United States;Hong Kong;Taiwan;Greece;Spain;Thailand;Ireland;Russian Federation;Israel;Italy;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Netherlands;Tunisia;Germany;China;Korea, Republic of